Upshaw–Schulman syndrome

Upshaw–Schulman syndrome
schistocytes in TTP marked in blue – H&E stain
Specialty	Rheumatology

Upshaw–Schulman syndrome (USS) is the

The ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 motif 13) gene is located on chromosome 9q34 and encoding 29 exons.^[6] The ADAMTS13 protease consists of 1427 amino acids and has several protein domains:^[1][6]

• The signal peptide is thought to have a role in the secretion, folding and stability of the ADAMTS13 protein.^[7] It interacts with membrane phospholipids and protein components of the secretory machinery within the cells.^[7]
• The metalloprotease domain contains the active site, which cleaves the unfolded VWF within the A2 domain, between the amino acids Tyrosine1605 and Methionine1606.^[8]
• The disintegrin domain together with the TSP1 repeat, the following cysteine-rich and spacer domains are necessary for
  substrate recognition, binding and cleavage^[7] of the VWF-A2 domain.^[8] First, the spacer domain recognizes VWF, increasing the affinity of ADAMTS13 to VWF. Next the disintegrin-like domain engages in a low-affinity binding. Then the metalloprotease domain interacts with the VWF, similar to a three-step molecular zipper.^[9]
• The TSP1 repeats mediate extracellular matrix protein-protein interactions.^[5]
• The cystein-rich domain is responsible for attachment, for example, to integrins of different cell membranes.^[5]
• The CUB domains take part in protein-protein interactions^[5] with VWF domains, which become exposed under shear stress,^[8] and are also involved in the binding and cleavage of VWF.^[7] Additionally they are involved in the ADAMTS13 protein secretion^[10]

Disease causing mutations in ADAMTS13, which can be found in all ADAMTS13 protease domains.^[8] result predominantly in impaired ADAMTS13 secretion with or without decreased ADAMTS13 protease activity.^[7] More than 120 disease causing mutations and numerous single-nucleotide polymorphisms (SNP) are known today.^[11][12] Residual ADAMTS13 activity has been observed with certain mutations and seems to be associated with a later disease-onset.^[11] It has been postulated that some SNPs interact with each other and may amplify or reduce overall ADAMTS13 activity.^[6][7]

ADAMTS13 function and pathogenesis

The ADAMTS protease family contains

Usually USS patients have a severely deficient ADAMTS13 activity of <10% of the normal.[9] In this low range there may be residual ADAMTS13 activity, depending on the underlying mutations.^[6][7][11]

In USS severe ADAMTS13 deficiency is often not enough to induce a (first) acute TTP episode. It primarily occurs when an additional (environmental) trigger is present.

After secretion, ADAMTS13 is either bound to the endothelial surface or free in the blood stream.[3] The heightened shear stress in small- and microvessels alters the 3D-structure of VWF from the contracted globular form to its linear form.^[8] The linear VWF has now its active binding sites exposed, that are important to start blood coagulation.^[8] These sites bind platelets and blood vessel lesions by interlinking the stretched VWF with one another – a blood clot is formed.^[8] In its uncut form, (ultra large) VWF's heightened stickiness and interlinking causes spontaneous platelet binding and blood clotting.^[8] The linear VWF exposes the A2 domain, so that in the presence of enough ADAMTS13 activity it gets cut to its normal size.^[3] VWF in the normal length loses its heightened stickiness and spontaneous crosslinking activity to only form blood clots when needed.^[3]

Diagnosis

A diagnosis of TTP is based on the clinical symptoms with the concomitant presence of thrombocytopenia (platelet count below 100×10⁹/L) and microangiopathic hemolytic anemia with schistocytes on the blood smear, a negative direct antiglobulin test (Coombs test), elevated levels of hemolysis markers (such as total bilirubin, LDH, free hemoglobin, and an unmeasurable haptoglobin), after exclusion of any other apparent cause.^[1][2]

USS can present similar to the following diseases, which have to be excluded:

Of note is that pregnancy associated affections like pre-eclampsia, eclampsia, and HELLP syndrome can overlap in their presentation as pregnancy can trigger TTP episodes.^[19]

Patients with fulminant infections, disseminated intravascular coagulation, HELLP syndrome, pancreatitis, liver disease, and other active inflammatory conditions may have reduced ADAMTS13 activity, but almost never a relevant severe ADAMTS13 deficiency <10% of the normal.^[2][20]

A severe ADAMTS13 deficiency below 5% or <10% of the normal (depending on the definitions)

The therapy of an acute TTP episode has to be started as early as possible.[1]^[2] The standard treatment is the daily replacement of the missing ADAMTS13 protease in form of plasma infusions or in more severe episodes by plasma exchange. In the latter the patients plasma is replaced by donated plasma.^[23] The most common sources of ADAMTS13 is platelet-poor fresh frozen plasma (FFP)^[3] or solvent-detergent plasma.

The benefit of plasma exchange compared to plasma infusions alone may result from the additional removal of ULVWF.^[1][23] In general both plasma therapies are well tolerated, several mostly minor complications may be observed.^[2][23] The number of infusion/exchange sessions needed to overcome a TTP episode are variable but usually take less than a week in USS.^[1][9] The intensive plasma-therapy is generally stopped when platelet count increases to normal levels and is stable over several days.^[1][2]

Preventive therapy

Not all affected patients seem to need a regular preventive plasma infusion therapy, especially as some reach long-term remission without it.^[24] Regular plasma infusions are necessary in patients with frequent relapses and in general situations with increased risk to develop an acute episode (as seen above) such as pregnancy. Plasma infusions are given usually every 2–3 weeks to prevent acute episodes of USS,^[16] but are often individually adapted.

Outlook

Several therapy developments for TTP emerged during recent years. Artificially produced ADAMTS13 has been used in mice^[25] and testing in humans has been announced. Another drug in development is targeting VWF and its binding sites, thereby reducing VWF-platelet interaction, especially on ULVWF during a TTP episode.^[26] Among several (multi-)national data bases a worldwide project has been launched to diagnose USS patients and collect information about them to gain new insights into this rare disease with the goal to optimize patient care.^[27]

Epidemiology

The

TTP was first recognized as a disease in 1947 and the name was given according to symptoms and underlying pathophysiology which differed from the already known immune thrombocytopenia.^[16] Schulman reported a case of TTP in 1960^[1] and Upshaw published a paper in 1978 about relapsing TTP in a patient whom he had followed for 11 years.^[31] In his report Upshaw noted the similarities with the reported case by Schulman and hypothesized that the two cases had similar causes – a missing plasma factor.^[1][31]

One year later the disease was named Upshaw-Schulmann Syndrome.^[32] In 1996 the VWF-cleaving protease was discovered and in the following year found to be the major issue in TTP's pathogenesis.^[15][33][34] In 2001 the VWF-cleaving protease was identified as ADAMTS13, the gene was mapped to chromosome 9q34, and the first USS-causing mutations were identified.^[1][17]

References